“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
Willow Biosciences, a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ing...
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...
This strategic acquisition marks a pivotal step towards creating a combined entity with expanded capabilities and a robust service offering that spans from...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Aizon, the AI SaaS provider transforming pharmaceutical manufacturing, announced today the closing of a $20 million...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of co...
“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” s...
Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this yea...
Novartis, under the leadership of CEO Vas Narasimhan, has announced robust financial results for the full year of 2023. The company reported a 10% growth i...
© 2024 Biopharma Boardroom. All Rights Reserved.
